BOSTON (Oct. 24, 2024) – Anaphylaxis can come on suddenly and without warning, and because its symptoms can be fatal, it is scary for those who encounter it. Two new studies being presented at this ...

The event will provide an overview of Nasus Pharma and NS002, the Company’s epinephrine intranasal powder candidate in development for the treatment of anaphylaxis. The current standard of care for ...

The main treatment for anaphylaxis is epinephrine, usually given by injection. If you don’t have access to epinephrine, call 911 or seek emergency care immediately. The most effective way to manage ...

Anaphylaxis is an emergency and may be life threatening if not attended to promptly. If a person is suspected to be having an attack of anaphylaxis, he or she should be immediately brought to the ...

Both doses will be supplied in single-dose, prefilled syringes for manual injection. The Food and Drug Administration (FDA) has approved a 0.15mg dose of Symjepi (epinephrine; Sandoz) to treat ...

Please provide your email address to receive an email when new articles are posted on . “The practice parameter on the emergency department diagnosis and treatment of anaphylaxis represents another ...

Symjepi should only be injected into the anterolateral aspect of the thigh; injection into other areas such as the buttocks or the hands and feet may result in adverse effects and may also not provide ...

A groundbreaking consensus report on anaphylaxis – the severe reaction some people experience from bee stings, peanut butter exposures, medications, and the like – has been released by the Global ...

Misinformation and outdated protocols contribute to the suboptimal management of anaphylaxis by patients and healthcare professionals, based on data from two new studies presented at the American ...

Nov. 15, 2004 (Boston) -- Epinephrine in most cases is safe to treat patients with acute anaphylactic reactions, report California researchers here in a poster presentation at the American College of ...

ARS Pharma had high hopes that the FDA on Tuesday would approve its flagship product, a needle-free treatment for adults and children with severe allergic reactions. But instead, the drugmaker was set ...